Skip to main content

Table 2 Microbiological data in study groups

From: Appropriateness of empiric antimicrobial therapy with imipenem/colistin in severe septic patients: observational cohort study

Subgroups

Appropriate EAMT group (n = 41)

Inappropriate EAMT group (n = 38)

Enlargement (n = 22)

Change (n = 9)

De-escalation (n = 7)

Bacteriologic documentation, n

28/41

18/22

9/9

7/7

NI location

 VAP

22

11

2

4

 Bacteraemia

3

7

3

2

 CRI

2

5

3

0

 CRB

1

1

0

1

 UI

0

1

1

0

Isolates (n)

 Acinetobacter B

14

6

0

0

 Klebsiella pneumonia

6

4

0

0

 Pseudomonas spp.

5

5

3

5

 Enterobacter

2

4

1

0

 E. coli

0

1

0

0

 Staphylococcus

0

4

1

0

 Enterococcus

0

3

1

0

 Stenotrophomonas M

0

3

2

0

 Burkholderiacepacia

1

0

0

0

 Streptocoque spp.

0

0

0

2

 Candida species

0

7

1

0

Antimicrobial adjustment

Imipenem/colistin

Imipenem/colistin/Glycopeptid (n = 8)

Other betalactam (for resistance to impenem)  + tygecycline, aminoglycoside or quinolone (n = 6)

Piperacilline (n = 2)

Imipenem/colistin/antifungal (n = 7)

Glycopeptide ± aminoside (n = 2)

Ceftazidime (n = 3)

Imipenem/colistin/Tygecycline/aminglyosides (n = 3)

Antifungal (n = 1)

Cefotaxime (n = 2)

  1. EAMT, empiric antimicrobial therapy; NI, nosocomial infection; VAP, ventilator acquired pneumonia; CRI, catheter related infection; CRB, catheter related bacteraemia; UI, urinary infection